Sun Pharmaceutical Industries Limited introduced tedizolid phosphate tablets 200 mg in India with the brand name "Starizo". Starizo (tedizolid phosphate) is a new antibiotic in the oxazolidinone class, prescribed for acute bacterial skin and skin structure infections (ABSSSI). Sun Pharma has been granted permission by MSD to produce, develop, and sell tedizolid phosphate in India.
“Drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) causing ABSSSIs, are more challenging to treat due to the limited availability of effective treatment options in hospitals. With Starizo, we are introducing a treatment option which is effective and has the convenience of once-a-day dosing”, said Kirti Ganorkar, CEO - India business, Sun Pharma. “At Sun Pharma, it has always been our endeavour to introduce innovative medicines that help improve the quality of life of patients,” he added. Skin and soft tissue infections made up approximately 29-32% of all infections in India in 2018-2019, being the most prevalent type of infections. Treating ABSSSI becomes more complex due to additional health conditions like diabetes, obesity, and kidney and liver problems in these patients.
Over the last few decades, there has been a rise in the occurrence of invasive S. aureus infections leading to negative results and high rates of mortality. S. aureus causes nearly 33% of ABSSSIs, with MRSA making up a significant portion. The prevalence of MRSA in India has risen annually, going up from 28.4% in 2016 to 42.6% in 2021 (S. aureus infections). Bacteria that are resistant to drugs, like MRSA which leads to ABSSSIs, are harder to treat because there are few effective antibiotics available.
, CDSCO.jpg)
